# MeiraGTx Holdings plc (MGTX) · Edgar & Edgarette company card

> MeiraGTx Holdings (MGTX) grew revenue 145% in FY2025 to $81 million, operating margin -130% against a -15.8% median for biological products, (no diagnostic substances), equity -2.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1735438 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MGTX) · [JSON](https://www.pops4.com/boards/company/MGTX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $81M |
| Revenue growth, 1 year | 144.6% |
| Revenue growth per year | 21.2% |
| Operating margin | -130.2% (prior year -493.4%) |
| Net margin | -140.3% |
| Operating cash flow | −$46M |
| Capital spending | $4M |
| Free cash flow | −$50M |
| Cash | $66M |
| Long-term debt | — |
| Total assets | $244M |
| Total equity | −$6M |
| Equity ÷ assets | -2.4% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -14.65 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -130.2% in FY2025; revenue is hard to predict: its 80% range is ±84%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $81.4M (FY2025). Experience: revenue up 144.6% on the year, up 21.2% a year over 4 years; operating margin -130.2%, up from -493.4%. Soundness: equity -2.4% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $47.2M and $537.5M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $51.7M to $493.5M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -130.2% against a -15.8% median; growth 144.6% against 21.4%.

Range logged 2026-09-24, receipt f2c92d620cefb62c, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-23 ([filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926109824/0001104659-26-109824-index.htm))

## Recent filings

- 8-K · filed 2026-09-23 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926109824/0001104659-26-109824-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926095504/0001104659-26-095504-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926095491/0001104659-26-095491-index.htm)
- 8-K · filed 2026-07-07 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926080949/0001104659-26-080949-index.htm)
- 8-K · filed 2026-06-15 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926074085/0001104659-26-074085-index.htm)
- 10-Q · filed 2026-05-14 · [filing](https://www.sec.gov/Archives/edgar/data/1735438/000110465926060739/0001104659-26-060739-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001735438.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1735438

## Cite

POPS4, Edgar & Edgarette: MeiraGTx Holdings plc (MGTX) company card, from the company's own SEC filings, accessed 2026-11-08, https://www.pops4.com/boards/company/MGTX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.